Shareholders meeting

qtenma~k A new way for a new world September 11, 2026 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001. Bandra (E), Mumbai – 400 051. Ref: Scrip Code: 532296 Ref: Scrip Name: GLENMARK Dear Sirs, Sub: Proceedings and Scrutinizer’s Report of the 48th Annual General Meeting (AGM) of Glenmark Pharmaceuticals Limited (‘the Company’) held on September 11, 2026 The 48th AGM of the Company was held on Friday, September 11, 2026 at 2.00 p.m. through Video Conferencing (VC)/ Other Audio Visual Means (OAVM) and the webcast facility was provided to the members. In this regard, please find enclosed the following: 1. Summary of the proceedings of the 48th AGM of the Company as required under Regulation 30, Para A of Schedule - III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. (‘Listing Regulations’) - Annexure A. 2. Report of the Scrutinizer pursuant to Section 108 of the Companies Act, 2013 and Rule 20 of the Companies (Management and Administration) Rules, 2014 of today’s date - Annexure B. The Scrutinizer’s Report will be made available on the Company’s website at www.glenmarkpharma.com 3. Voting results of the business transacted at the AGM, as required under Regulation 44 (3) of the Listing Regulations is being filed in XBRL mode. This is for your Information and records. Thanking You, Yours Faithfully, For Glenmark Pharmaceuticals Limited Rashmi Khandelwal Company Secretary & Compliance Officer Encl: As above Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com qlenma~k A new way for a new world Annexure A Summary of Proceedings of the 48th Annual General Meeting The 48th Annual General Meeting (“AGM”) of the members of Glenmark Pharmaceuticals Limited (“the Company”) was held on Friday, September 11, 2026, through Video Conferencing (“VC”)/ Other Audio Visual Means (“OVAM”), in accordance with the circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India, and as per applicable provisions of the Companies Act, 2013 (the “Act”) and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”). The webcast facility was provided to Members. The AGM commenced at 2.00 p.m. Mr. Glenn Saldanha, Chairman cum Managing Director & CEO presided over the meeting and welcomed the Members, Directors and other dignitaries participating in AGM. All the Directors of the Board were present at the AGM including the Chairpersons of the Audit Committee, Nomination and Remuneration Committee, Stakeholders Relationship Committee, Risk Management Committee and CSR Committee were present at the AGM. The Chief Financial Officer and Company Secretary were also present at the meeting. The representatives of Statutory Auditors, Cost Auditors, Secretarial Auditors and Scrutinizers were also present at the Meeting through VC. Total 54 Shareholders attended the Meeting. The requisite quorum being present, the Chairman called the Meeting to order. The Registers as required under the Companies Act, 2013 and other relevant documents mentioned in the Notice were available for inspection. Thereafter, the Company Secretary & Compliance Officer provided general instructions regarding participation at the meeting, stating that the Notice of the AGM along with Integrated Annual Report for FY 2025-26 was sent through electronic mode to all the Members whose e-mail addresses were registered with the Depositories and those members whose e-mail ids were not registered with the Depositories were sent a letter containing the web-link where the complete details of Integrated Annual Report of the Company were placed. Since there was no physical attendance of Members and in compliance with the Circulars issued by MCA and SEBI, the requirement of appointing proxies was not applicable. The Chairman then delivered his speech by expressing heartfelt gratitude to the Members for their unwavering trust in the Company’s management, covering synopsis of the financial year 2025-26, Innovation, strengthening of commercial foundation, quality growth, people and responsibility and vision for the future etc. Thereafter, the Company Secretary & Compliance Officer informed the Members that, as the Notice convening the Meeting had already been circulated to all the Members, the same was taken as read. The Members were further informed that the Statutory Auditors' Report and the Secretarial Audit Report did not contain any qualification, reservation, adverse remark. Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, India T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com qlenma~k A new way for a new world The resolutions put forth at the 48th AGM were as under: Sr. Agenda Item Type of No. Resolution ORDINARY BUSINESS 1. To receive, consider, approve and adopt the Audited Standalone Financial Ordinary Statements of the Company for the Financial Year ended March 31, 2026, together with the reports of the Board of Directors and Auditors thereon. 2. To receive, consider, approve and adopt the Audited Consolidated Ordinary Financial Statements of the Company for the Financial Year ended March 31, 2026, together with the report of the Auditors thereon. 3. To declare dividend of Rs. 2.50/- per equity share for the financial year O r dinary March 31, 2026. SPECIAL BUSINESS 5. Re-appointment of Mrs. Blanche Saldanha as a Non-Executive Director, Special liable to retire by rotation. 6. To ratify remuneration of the Cost Auditor for the financial year ending Ordinary March 31, 2027. Thereafter, she apprised the Members with the e-Voting process stating that the Company had provided its members the facility to cast their vote electronically through the National Securities Depository Limited (“NSDL”) system before the Meeting. She also informed that the e-Voting facility was also made at the AGM for the benefit of Members who were present during the Meeting and had not casted their votes earlier through remote e-Voting. She further apprised about the appointment of M/s. Mehta & Mehta, Company Secretaries as the Scrutinizer to conduct the e-Voting process in a fair and transparent manner pursuant to the provisions of section 109 of the Companies Act, 2013. Then Chairman invited the Members to express their views, ask questions and give suggestions. The Company has received requests from 15 members to speak during the AGM. However, 1 speaker member did not join the AGM. After giving sufficient time to all the speaker members, Mr. Glenn Saldanha, Chairman & Managing Director, and Mr. Anurag Mantri, Executive Director & Global Chief Financial Officer appropriately responded to the queries raised by them. The Chairman further informed the members that who have still not casted their votes may do so through the NSDL e-Voting facility available on the same portal. The e-Voting shall close in another Thirty minutes after conclusion of AGM. He further informed that the combined results of the remote e-Voting as well as e-Voting during at the AGM along with the Scrutinizer's Report would be announced within the statutory time permitted Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, India T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumb [Showing first 8,000 characters — download PDF for full document]